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Abstract
Herpes simplex virus 1 is a common human pathogen that causes an initial productive
infection followed by a lifelong latent infection of sensory neurons. Although the active
infection is self-limiting in healthy populations, HSV can pose serious health risks to
immunocompromised individuals.

Furthermore, drug-resistant strains o f HSV-1 have

emerged in the human immunodeficiency virus (HIV) afflicted populations, necessitating
the development o f efficacious treatment options to combat HSV-1 infections. In recent
years, plant derived products have gained popularity as promising antiviral agents.
Studies of plant-derived compounds, including polysaccharide extracts from algae and
hydrolyzable tannins, indicated that antiviral activity may be contributed to the plant
extract’s inhibition o f binding and penetration o f the virus in cell cultures. Curcumin, a
polyphenol derived from the Curcuma longa plant, has gained attention as an antiviral
therapeutic agent after research publications suggested the compound exhibits
antioxidant, antiproliferative, anti-inflammatory, and microbicidal properties. Curcumin
has demonstrated in previous studies to modulate numerous cellular signaling pathways.
Additionally, curcumin has been indicated as an effective inhibitor o f HSV-2 in HeLa
cell cultures and as an inhibitor o f HSV-1 infectivity, immediate-early gene expression
and replication in Vero cell cultures.

The results of this study suggest that curcumin

indeed exhibits antiviral properties against HSV-1 in Vero cell cultures. HSV-1 viral
particles appeared to successfully bind and penetrate Vero cells.

However, the

replication o f the virus was interrupted after the virus gained entrance to the Vero cells,
resulting in a reduction in HSV-1 titer for the Infectious Dose 50 (ID 5o)and diminished
signal strength of HSV-1 in curcumin-treated ceils as viewed by gel electrophoresis. This

evidence supports the inhibitory effects o f curcumin on HSV-1, warranting further
investigation into the antiviral capacities o f this biologically active plant-derived
compound.
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Introduction
Herpes simplex virus type 1 (HSV-1) is a member o f the Herpesviridae family o f viruses.
Although the Herpesviridae family contains over one hundred herpesviruses that can
infect various species o f fish, birds, horses, and humans, HSV-1 is only one o f eight
Herpesviridae known to infect humans; no animal reservoirs are known (Akhtar &
Shukla, 2009).

HSV-1 is a relatively large, double-stranded deoxyribonucleic acid

(dsDNA) virus that is a member o f the subfamily Alphaherpesviridae.

The

Alphaherpesviridae are distinguished by a short eighteen hour lifecycle, rapid spread,
destruction of host cells, and the establishment o f a latent infectious cycle (Mettenleiter,
Klupp, & Granow, 2009; Roizman & Baines, 1991). The closest phylogenic relative to
the alphaherpesviruses is the varicella-zoster virus, the cause o f the common childhood
illness chickenpox.

Other herpes virus families include the betaherpesviruses,

specifically cytomegalovirus, human herpes viruses 6 and 7, and the gammaherpesviruses
Epstein-Barr virus and human herpesvirus 8, otherwise known as Kaposi’s sarcomarelated virus (Roizman & Baines, 1991).

Greater than eighty percent o f the adult

population in the world possess antibodies to HSV-1 and harbor the latent form o f the
viral genome in their peripheral nervous systems (Akhtar & Shulka, 2009).

The

establishment of this lifelong, latent infection that has the ability to reactivate and cause
one or more rounds o f the disease is a noteworthy hallmark o f a herpesvirus infection
(Rao et al., 2011). No vaccine has been successfully developed to prohibit the virus from
establishing latency in neurons because the intimate contact o f peripheral neurons with
epithelial cells enables movement o f the virus particles in and out o f the nervous system
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without exposure to circulating antibodies, and this immune avoidance by HSV-1
presents difficulty in developing an effective vaccine against the virus (Rao et al., 2011).
HSV-1 is transmitted when mucous membranes or abraded skin is exposed to lesions or
mucosal secretions o f an individual with an active HSV-1 infection (Fatahzadeh &
Schwartz, 2007).

Additionally, HSV-1 has been demonstrated to shed onto skin and

fomites, including utensils and clothing, permitting unsuspecting individual’s exposure to
the virus (Fatahzadeh & Schwartz, 2007). HSV-1 can be transmitted from mother to child
in utero or during childbirth (Fatahzadeh & Schwartz, 2007). HSV-1 mainly infects oral,
pharyngeal,

and

ocular

sites.

HSV-1

infections

include

primary

herpetic

gingivostomatitis (PHGS), herpes simplex labialis (HSL), recurrent intraoral herpes
(RIH), genital herpes, Kaposi’s varicelliform eruption (KVE), herpes gladitorum,
herpetic whitlow, ocular herpes, including stromal keratitis, encephalitis, and neonatal
herpes (Fatahzadeh & Schwartz, 2007; Lin et al., 2011).

Symptoms associated with

HSV-1 infections are dependent upon the host’s genetic composition, immune status, site
of primary infection, and dose o f viral inoculum (Fatahzadeh & Schwartz, 2007). The
most common form o f HSV-1 infections is orofacial lesions. The lesions develop in
and/or around the oral cavity o f the host.

These lesions are normally preceded or

accompanied by a buming/stinging sensation, pain and discomfort. Lesions are formed
when vesicles at the infection site rupture to eventually form ulcerations and symptoms
can persist for two weeks and viral shedding can continue up to several weeks after the
resolution of symptoms (Fatahzadeh & Schwartz, 2007). HSL and RIH are the most
common forms of HSV-1 infections. HSL affects the outer vermilion border, the border
that marks the transition from lips to skin, and is normally associated with an ulcerative
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region’s crusting over, forming a scab while RIH affects the hard palate, surrounding
gingiva, and keratinized tissues o f the oral cavity, producing an ulcerative region more
commonly known as a canker sore or aphthous ulcer (Fatahzadeh & Schwartz, 2007).
Additionally, HSV-1 can cause genital herpes which is localized to the labia minora and
urethra meatus in women and the shaft and glans o f the penis in men (Fatahzadeh &
Schwartz, 2007). However, most HSV-1 infections are not life-threatening except in the
case o f neonates and immunocompromised patients.

Classification:

HSV-1 is a dsDNA virus with a diameter o f approximately 200 nm. The genome consists
o f 152kb (Rode et al., 2011; Svobodova, Bell, & Crump, 2012). Additionally, the linear
genome contains 30 to 35 different proteins and two main protein coding components—
the unique long (U l) segment, containing 59 genes and a short region—the unique short
(Us) segment, containing 14 genes, and within each of these regions, inverted repeat
sequences exist both internally (IRL, IRS) and terminally (TRL, TRS).

The HSV-1

genome is able to recombine through the repeat sequences to form four equimolar
isomers in which the U l and Us sequences are inverted with respect to one another
(Wadsworth, Jacob, & Roizman, 1975). Furthermore, the three replication origins (Ori)
exist along with 84 open reading frames (Martin, Deb, Klaur, & Deb, 1991). The dsDNA
genome resides within the 100-110 nm diameter icosahedral nucleocapsid which is
surrounded by a complex proteinaceous tegument layer (Akhtar & Shukla, 2009). This
tegument layer consists of greater than 15 known proteins and is in turn surrounded by a
lipid

envelope

which contains

approximately

10 viral

envelope

glycoproteins
3

(Fatahzadeh & Schwartz, 2007)). These glycoproteins are essential for establishing a
productive herpes virus infection.

Infection Cycle:

Productive (Lytic) Infection
Specific transcriptional strategies are characteristic o f viruses with DNA genomes during
the productive infectious cycle and HSV-1 is no exception. Viral genes are transcribed in
a reproducible and precise chronological sequence which ensures efficient gene
expression and regulatory functions, ease o f transition from one transcriptional stage to
the next, and the successful encoding o f virion structural proteins (Svobodova et al.,
2012). Three categories of genes are represented in HSV-1 genome replication and
follow a specific sequential transcriptional cascade upon entry into the host cell—
immediate early (a), early (p), and late (y) (Kalamvoki & Roizman, 2011) a proteins
ICPO (infected cell protein 0) and ICP4 are transported directly to the nucleus and are
responsible for regulating the transcription o f immediate early genes and for activating
the transcription of early genes, P proteins, and interacting with cellular RNA polymerase
II (Nagel et al., 2011; Lester & Deluca, 2011). ICPO is required for efficient viral gene
expression, replication, and reactivation from latency (Mostafa et al., 2011). VP 22, a
major component of the HSV-1 tegument, has been implicated in the recruitment o f ICPO
from the cytosol to ICPO-specific domains in the cytoplasm, a necessary step in the viral
assembly pathway (Gillian, Hafezi, & Bernard, 2005; Maringer & Elliott, 2010).
Additionally, a proteins counteract host cellular silencing responses and increase the rate
of core histone chromatin exchange, promoting HSV-1 gene expression (Conn, Hendzel,
4

& Schang, 2011). The p proteins ICP8, UL42, and thymidine kinase function primarily
in viral DNA replication and production substrates for DNA synthesis (Liptak,
Uprichard, & Knipe, 1996). y proteins gB, gC, gD, and gH are virion structural proteins
required for virus assembly and particle egress; y proteins are produced on and inserted
into the membranes o f the rough endoplasmic reticulum and y proteins are also
transported to the nucleus for assembly o f the nucleocapsid and for DNA packaging
(Farnsworth, Goldsmith, & Johnson, 2003; Farnsworth et al., 2007; Rode et al., 2011).

The primary HSV-1 infection begins in epithelial cells at mucosal surfaces. The virus is
transmitted through saliva into the eyes or breaks in the skin. The host’s intrinsic and
innate defenses, including interferon (IFN) and cytokines, limit the spread o f the infection
at this stage (Mossman & Ashkar, 2005). The virions may infect local immune effector
cells, including dendritic and natural killer (NK) cells, and virions spread locally between
epithelial cells and may even spread deeper to fibroblasts, capillary endothelial cells,
sweat glands, and hair follicles (Mossman & Ashkar, 2005). Antibody neutralization to
HSV-1 is non-existent, as the virus is spread through cell-to cell contact, not through the
hematogenous or lymphatic route (Akhtar & Shukla, 2009). Virions are released from
the basal surface in close proximity to sensory nerve endings.

HSV-1 spreads from

neuron to neuron at or near sites o f synaptic contact (Akhtar & Shukla, 2005; Fatahzadeh
& Schwartz, 2007). The virion envelope glycoproteins fuse with cell receptors on plasma
membranes of nerve endings in a pH-independent manner, releasing the nucleocapsid
with the inner tegument proteins into the axoplasm (Akhtar & Shukla, 2009). HSV-1
virions then bind to the extracellular matrix glycosaminoglycans, including heparin
sulfate and/or chrondroitin sulfate via envelope glycoproteins gB and gC (Lin et al.,
5

2011).

Viral protein gD interacts with a second cellular receptors, nectin-1, nectin-2

(members of the immunoglobulin superfamily), and herpesvirus entry mediator (HVEM;
a member of the tumor necrosis factor receptor family) which are found primarily at
junctions o f epithelial cells and the synaptic junctions o f neurons and undergoes a
conformational change which in turn recruits gH and gL (Akhtar & Shukla, 2009; Lin et
al., 2011). Additionally, viral protein gD may interact with a modified heparin sulfate
molecule, 3-O-sulfated heparin sulfate, which is found in corneal cells (Akhtar & Shukla,
2009). Viral and plasma membrane fusion is mediated by viral glycoproteins gD, gB,
gH, and gL (Akhtar & Shukla, 2009). When membrane fusion occurs, tegument proteins
and the HSV-1 nucleocapsid are released into the host cell’s cytoplasm (Akhtar &
Shukla, 2009).

Viral nucleocapsids are then transported on microtubules by dynein

motors over long distances to the neuronal cell bodies that innervate the infected
peripheral tissue where the viral DNA enters host cell’s nucleus through attachment with
microtubules (Rode et al., 2011).

After viral adsorption, some tegument proteins are

transported to the nucleus while others remain in the cytoplasm. The HSV-1 icosahedral
nucleocapsid docks at the nuclear pore and releases viral DNA into the host cell’s
nucleus. Viral tegument protein (VP) 16 interacts with the host cell transcription proteins
to stimulate the transcription of the immediate-early (a) genes by the host cell RNA
polymerase II (Conn, Hendzel, & Schang, 2011).

Some immediate-early mRNAs are

spliced and transported to the cytoplasm and translated. VP 16 recruits HCF-1. Oct-1 and
LSD-1 to response elements o f immediate-early promoters while a proteins are
transported to the nucleus to activate the transcription o f early genes and regulate
transcription o f immediate-early genes (Kalamvoki & Roizman, 2011).

Early gene
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transcripts (p) are then transported to the cytoplasm and translated. These P proteins
function primarily in viral DNA replication and production o f substrates for viral DNA
synthesis; some P proteins are transported to the nucleus while some remain in the
cytoplasm (Liptak, Uprichard, & Knipe, 1996). Viral DNA synthesis is then initiated at
HSV-1 Ori and DNA replication and recombination produces a long, concatemeric DNA
template for late-gene expression (Martin, Deb, Klaur, & Deb, 1991). Late proteins (y)
are primarily virion structural proteins which are necessary for virus assembly and
particle egress; y proteins may also insert into the membranes o f the rough endoplasmic
reticulum (Farnsworth, Goldsmith, & Johnson, 2003; Farnsworth et al., 2007; Rode et al.,
2011). Furthermore, membrane proteins may be modified by glycosylation and precursor
glycoproteins are transported to the Golgi apparatus for modification and processing
while mature glycoproteins are then transported to the plasma membrane o f the infected
cell. The newly replicated viral DNA is packaged in nucleocapsids and buds from the
inner nuclear membrane into the perinuclear lumen along with tegument proteins to form
an envelope. These immature enveloped virions fuse with the outer nuclear membrane
from within, releasing the nucleocapsid into the cytoplasm while leaving behind viral
membrane proteins. The tegument proteins which were added in the nucleus remain with
the nucleocapsid. The nucleocapsids bud into late golgi-endosome compartment, acquire
an envelope containing a mature viral envelope and proteins and a complete tegument
layer. The enveloped HSV-1 particle buds into a vesicle, is transported to the plasma
membrane, and is finally released by exocytosis (Akhtar & Shukla, 2009; Lin et al., 2011;
Mettenleiter, Klupp, & Granow, 2009).

Acute infection commences in the affected

ganglions, resulting in ulcerative lesions. Because peripheral nervous system ganglia are
7

in close proximity to the bloodstream, HSV-1 is exposed to lymphocytes and humoral
effectors o f the immune system and the infected ganglia become inflamed and populated
with lymphocytes and macrophages, leading to cell-mediated immunopathology and the
appearance o f symptoms (Fatahzadeh & Schwartz, 2007; Mossman & Ashkar, 2005).
Cell mediated immunity is required for the resolution o f the HSV-1 infection while
ganglion infection is resolved within seven to fourteen days after the primary infection
ensues and at this point, long term latent infection is established (Fatahzadeh & Schwartz,
2007).

Latent Infection:
The latent HSV-1 infection occurs primarily in the neuronal ganglia o f the peripheral
nervous system (Held et al., 2011). Neurons do not undergo mitosis, thus no further viral
replication is required for HSV-1 to persist in the latent state. Furthermore, HSV-1 rarely
spreads to the central nervous system even though the virus is in direct synaptic contact
with the peripheral nervous system (Fatahzadeh & Schwartz, 2007). This life cycle is
similar to lytic infection, except that the viral DNA circularizes in the nucleus and wraps
around nucleosomes (Su et al., 2002). The nucleosome-covered viral genome is tethered
in the nucleus to cellular chromatin. The latent HSV-1 genome is transcriptionally silent
as only a single pre-mRNA is produced from the latency-associated transcript (LAT)
promoter (Wang et al., 2005). LAT RNA is spliced and forms a stable intron in the form
of a lariat which is maintained in the cell’s nucleus.

The spliced LAT mRNA is

transported to the cytoplasm where several small open reading frames may be translated.
When cellular proteins are produced in response to changes in neuronal physiology
8

induced by trauma such as tissue and nerve damage, surgery, hormonal changes, fever,
fatigue, immunosuppression, steroids, sunlight, and physical and psychological stress,
viral replication is initiated as HSV-1 can travel either in the antiretrograde direction and
reinfect epithelial tissue or in the retrograde direction to infect synaptically linked
neurons, hence the productive infection cycle commences (Fatahzadeh & Schwartz,
2007; Lin et al., 2011).

ICPO phosphorylation and reactivation appears to be a

contributing factor of HSV-1 switching from the latent to the lytic cycle (Everett, Parsy,
& Orr, 2009; Mostafa et al„ 2011).

Diagnosis and Treatment:
The

majority

of HSV-1

immunocompromised

and

infections
neonate

are

non-life

population,

threatening,

especially

except

in the

in

case

the
of

keratoconjunctivitis, meningitis, and encephalitis (Lin et al., 2011). Detection o f HSV-1
normally is performed through the propagation o f viral cultures and the subsequent direct
cell observations of cytopathetic effect.

In addition, immunohistochemistry

such as

direct fluorescent antibody testing can be incorporated to detect HSV-1 antigens present
in specimen

The Chemicon SimulFluor® immunofluorescence assay simultaneously

diagnoses HSV-1, HSV-2 and varicella-zoster virus (VZV) in vesicular, oral, genital and
skin lesions (Chan, Brandt, & Horsman, 2001). Polymerase chain reaction can detect
HSV-1 DNA in clinical specimens and is the most precise and sensitive o f diagnostic
tools especially when determining the subspecies of virus present, and to confirm
encephalitis (Fatahzadeh & Schwartz, 2007). Furthermore, after a conclusive diagnosis is
9

determined, therapeutic antiviral treatments are introduced. These antiviral treatments
however only limit the symptoms o f HSV-1 by inhibiting viral replication. Normally
topical antiviral agents are applied to accessible lesions and inaccessible lesions are
treated with systemic antiviral agents, either orally or intravenously.

Acyclovir

(Zovirax®) is the most commonly prescribed antiviral agent to combat HSV-1, both
topically and systemically (Fatahzadeh & Schwartz, 2007).

Acyclovir is a synthetic

guanosine analogue which displays an affinity for thymidine kinase, a protein encoded by
HSV.

Acyclovir stops replication if HSV by competitive inhibition o f viral DNA

polymerase, incorporation into and termination o f the growing viral DNA chain, and the
inactivation o f viral DNA polymerase (Lin et al., 2011). The drug has relatively mild
side effects, including nausea, diarrhea, and general malaise although an extremely rare
but serious side effect includes renal impairment/failure while acyclovir has low average
oral bioavailability, low plasma protein binding, and short plasma elimination half-life,
thus requiring frequent dosage for optimum therapeutic value (Arduino & Porter, 2006;
Lin et al., 2011).

Furthermore, acyclovir resistant strains of HSV have surfaced,

especially in HIV-positive patients, warranting the urgent development o f new drugs to
combat HSV infections (Lin et al., 2011).

Foscamet (Foscavir®), a viral DNA

polymerase-targeting inhibitor has been employed in acyclovir-resistant patients but has
also been hindered by drug resistance (Danve-Szatanek et al., 2004; Lin et al., 2011).
Helicase-primase inhibitors (HPI) have proven promising as new therapeutic agents
against HSV.

HPI targets the UL5/8/52 helicase-primase complex essential for HSV

DNA synthesis. Higher potency against HSV has been established with this class o f
drugs in both cell culture and animal models, although resistant laboratory strains o f HSV
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have been reported (Biswas, Miguel, Sukla, & Field, 2009; Biswas, Swift, & Field,
2007). Vaccine development against HSV viral glycoprotein D has proven efficacious,
with a recent study suggesting that vaccination was successful against HSV-1 genital
infections (Belshe et al., 2012). New topical therapeutic compounds must be identified to
inhibit the sexual transmission o f HSV disease, especially considering the emergence o f
drug-resistant strains in the HIV population (Harden, Falshaw, Camachan, Kern, &
Prichard, 2009).

Curcumin:

Curcumin (diferuloylmethane) is a polyphenol extracted from the plant Curcuma longa, a
member o f the ginger family Zingiberaceae. Curcumin is the main chemical component
of turmeric powder extracted from the rhizome o f this plant.

The extract has been

employed in Ayurveda, the Indian system o f medicine for 6000 plus years (Aggarwal,
Kumar, & Bharti, 2003; Beevers & Huang, 2011). Curcumin is a natural yellow orange
dye that is commonly used as a spice, flavoring agent, food preservative and coloring
agent.

Furthermore, studies have demonstrated that curcumin is a potent antioxidant,

anti-inflammatory, antiproliferative, and anti-atherosclerotic (Aggarwal, Kumar, &
Bharti, 2003; Beevers & Huang, 2011; Si et al., 2007). Curcumin has been shown to
inhibit scarring, gallstone, and cataract formation; promote wound healing, muscle
regeneration; prevent liver injury and kidney toxicity; exert medicinal benefits against
psoriasis, diabetes, multiple sclerosis, Alzheimer’s, HIV, septic shock, cardiovascular
disease, lung fibrosis, arthritis, and inflammatory bowel disease (Aggarwal, Kumar, &
Bharti, 2003; Beevers & Huang, 2011).

Additionally, current research suggests that
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curcumin may exhibit chemotherapeutic and chemopreventative properties against
various cancers, including breast cancer, colon cancer, kidney cancer, liver cancer,
leukemia, basal cell carcinoma, prostate cancer, rhabdomyosarcoma, and melanoma
(Beevers & Huang, 2011). Curcumin has effectively demonstrated inhibitory properties
for the major stages o f carcinogenesis including transformation, initiation, promotion,
invasion, angiogenesis, and metastasis (Beevers & Huang, 2011).

Commercially

available curcumin contains three major components: curcumin, demethoxycurcumin
(curcumin II), and bis-demethoxycurcumin (curcumin III) which together are known as
the cucuminoids (Aggarwal, Kumar, & Bharti, 2003; Beevers & Huang, 2011).
Curcumin is insoluble in water but is soluble in the organic solvents methanol and
dimethylsulfoxide
gastrointestinal

(DMSO)

absorption,

(Beevers
limiting

&
its

Huang,

2011).

bioavailability

Curcumin
and

has

effectiveness

poor
when

administered orally and curcumin toxicity is low, as little side effects were reported in
human clinical trials at doses up to 10g/day (Aggarwal, Kumar, & Bharti, 2003).
Curcumin has been proven to be phototoxic against bacteria and could possibly be
application in the topical phototherapy o f psoriasis, cancer, bacterial, and viral diseases
(Aggarwal, Kumar, & Bharti, 2003).

Current HSV research has focused on the development o f topical microbicides that prove
efficacious against the virus, especially in HIV-positive women.

Limiting the sexual

transmission o f the virus has become imperative as the HIV-positive population
continues to expand. Plant-derived compounds have displayed antimicrobial activity and
remain popular research options in part because o f their low toxicity, suggested
effectiveness in laboratory studies, and low developmental cost (Bourne, Bourne,
12

Reising, & Stanberry, 1999; Harden et al., 2009). Curcumin demonstrated bactericidal
effects against gram positive and gram negative bacteria by disrupting bacterial cell walls
(Beevers & Huang, 2011). Furthermore, curcumin exhibited antiviral activity against
HSV-2 in HeLa cell lines and HSV-1 infectivity, immediate-early gene expression and
replication in Vero cell cultures (Bourne, Bourne, Reising, & Stanberry, 1999; Kutluay,
Doroghazi, Roemer, & Triezenberg, 2008). Prior studies illustrated that curcumin slows
but does not totally block HSV-1 replication, thus suggesting that viral adsorption is not
completely hindered (Kutluay, Doroghazi, Roemer, & Triezenberg, 2008). Additional
evidence has suggested polysaccharide extracts effectively inhibit HSV-1 binding to the
host cell (Harden et al., 2009). Polyphenolic secondary metabolites have demonstrated to
hinder viral adsorption to the host cell membrane and inhibit penetration o f HSV-1 (Lin
et al., 2011). Therefore, to further evaluate the effectiveness o f curcumin on HSV-1, this
study will attempt to identify the mechanism o f viral inhibition in Vero cells. To
determine if curcumin inhibits binding o f HSV-1, penetration o f HSV-1 and/or
replication of HSV-1, first the cytotoxicity o f curcumin on Vero cells must be established
utilizing a trypan blue assay. After a safe concentration o f curcumin on the Vero ceil line
is determined, the inhibitory effects o f curcumin on HSV-1 propagation in Vero ceils will
be investigated through the incorporation of plaque assays, spectrophotometry, and
subsequent gel electrophoresis o f viral gene products.
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Materials and Methods

Cells:

Cell line. Vero (African green monkey kidney cells [American Type Culture
Collection (ATCC), Manassas, VA, USA] were grown in Dulbecco modified minimum
Eagle’s medium (DMEM) (Mediatech Incorporated, Manassas, VA, USA) supplemented
with 5% fetal bovine serum (FBS) (Biowest, Miami FL, USA) and 1% gentamicin
(Lonza, Walkersville, MD, USA).

Cell cultures. Vero cells were maintained in T25 flasks with 5 mL 5% FBSDMEM in a 37°C incubator with an atmosphere o f 5% CO 2 . To passage the Vero cells,
the 5% FBS-DMEM was removed and the cells were washed twice with 5.0 mL IX
phosphate buffered saline (PBS) (Fisher Scientific, Fair Lawn, NJ, USA) supplemented
with 1% gentamicin.

Cells were trypsinized with 0.5mL o f IX trypsin-EDTA

(Mediatech Incorporated, Manassas, VA, USA) at 37°C with an atmosphere o f 5% CO 2
for 5 minutes to detach cells. 4.5 mL fresh 5% FBS-DMEM was added to the flask,
removed and discarded. An additional 4.5mL o f 5% FBS-DMEM was then added to the
flask to maintain the 5.0 mL total volume. Cells were maintained at a ratio of 1:10 and
subcultured one time per week.

Virus. A recombinant strain of HSV-1, GHSV-UL46, was incorporated in all
experiments (ATCC, Manassas, VA, USA). The recombinant strain contains a sequence
for green fluorescent protein (GFP) fused to tegument protein pUL46. To prepare HSV1, a T25 flask with Vero cells was prepared as described in the cell culture section.
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When cells were approximately 70% to 80% confluent, media was poured o ff the cells
and 200pi o f HSV-1 was added to the flask. The flask was then incubated at 37°C with
an atmosphere of 5% CO 2 for one hour with intermittent rocking. Six mL of 5% FBSDMEM was added and the flask was incubated for 48 hours at 37°C and an atmosphere
o f 5% CO 2. The lysate was harvested and centrifuged in a 15ml conical tube for 10
minutes at 4500 rpm to remove cellular debris. The lysate was aliquoted into cryogenic
vials and stored at

-80°C.

Curcumin. Curcumin (Sigma-Aldrich, Saint Louis, MO, USA) was dissolved in
dimethylsulfoxide (DMSO) (Fisher Scientific, Fair Lawn, NJ USA) to prepare an initial
4% solution of curcumin. Subsequent concentrations were prepared by diluting the prior
concentration by one-half, yielding concentrations o f 2%, 1%, 0.5%, 0.25%, 0.125%,
0.06%, 0.03%, and 0.015% respectively.
Cytotoxicity of Curcumin:

Trypan blue assay. Vero cells were plated in 6-well plates (Coming NY, USA)
with 2.5 mL of cell suspension added to each well and incubated at 37°C with an
atmosphere o f 5% CO 2 until confluent, approximately 24-48 hours.

The media was

aspirated from each well and 100 pi o f the curcumin concentrations was added to each
respective well; as controls, 100 pL o f 5% FBS-DMEM, 100 pL o f methanol, and 100
pL of DMSO were each added to separate wells. Plates were incubated at 37°C with an
atmosphere of 5% CO 2 for 1 hour with intermittent rocking every 15 minutes to ensure
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complete coverage o f cells with curcumin.

After 1 hour, any remaining curcumin

solution was aspirated from the cells and 3 mL o f 5% FBS-DMEM was added to each
well. The 6-well plates were then incubated at 37°C and an atmosphere o f 5% CO 2 for
48 hours.

2 mL o f 5% FBS-DMEM was then removed from each well.

The cell

monolayer o f each well was scraped with a sterile cell scraper and 100 pL o f the cell
suspension for each well was transferred to a separate Eppendorf tube. 100 pL o f trypan
blue solution (Mediateeh, Inc., Manassas, VA, USA) was then added to each separate
Eppendorf tube containing the cell suspensions.

After 1-2 minutes, 100 pL o f each

separate mixture in the Eppendorf tubes was loaded individually onto a hemacytometer
(Hausser scientific, Horsham, PA, USA) and observed under a Leica ATC 200
microscope at 400X magnification. Live cells (clear) and dead cells (dark blue) were
counted in the four comer squares and middle square of the grid. Total cells for each
curcumin concentration were calculated, in addition to the percent live cells.

Viral Inhibition:
C ell-treated virions. Vero cells were plated in 6-well plates with 2.5 mL o f cell
suspension added to each well and incubated at 37°C with an atmosphere o f 5% CO 2 until
confluent, about 24-48 hours. The media was aspirated and cells were treated with 100
pL o f each o f the nine concentrations o f curcumin; controls included 2 wells o f 100 pL o f
5% FBS-DMEM. Plates were rocked and incubated at 37°C with an atmosphere o f 5%
CO 2 for 15 minutes. Unabsorbed solution was aspirated and 100 pL o f stock virus was
added to each well, excluding the media control well (mock-infected) that contained 100
pL o f 5% FBS-DMEM. The plates were returned to the incubator at 37°C and 5% CO 2
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for 1 hour and rocked every 15 minutes to ensure complete coverage.

After 1 hour,

unabsorbed virus was aspirated from each well and 2.5 mL o f 5% FBS-DMEM was
added to each well. The plates were incubated at 37°C with an atmosphere o f 5% CO 2
for 48 hours.

At that time, the lysate from each well was harvested, transferred to

cryogenic vials, and stored at -80°C.

V irus-treated virions. Vero cells were plated in 6-well plates with 2.5 mL of
cell suspension added to each well and incubated at 37°C with an atmosphere o f 5% CO 2
until confluent, about 24-48 hours. 100 pL o f stock virus was mixed with 100 pL o f each
o f the curcumin concentrations for a total o f 9 Eppendorf tubes. The HSV-1 control tube
contained 100 pL of the 5% FBS-DMEM in place o f the curcumin plus 100 pL o f the
virus.

An additional control tube contained no virus, only 200 pL o f the 5% FBS-

DMEM.

The mixtures remained at room temperature (approximately 25°C) for 15

minutes. During this time, the media was aspirated from each well o f the 6-well plate.
200 pL of each mixture was added to separate wells on the 6-well plate. The plates were
returned to the 37°C incubator with an atmosphere o f 5% CO 2 for 1 hour with rocking
every 15 minutes. Unabsorbed virus/curcumin mixtures were aspirated from each well
and 2.5 mL of 5% FBS-DMEM was added to each well. The plates were once again
returned to the 37°C incubator with an atmosphere o f 5% CO 2 for 48 hours after which
the lysate was harvested, transferred to cryogenic vials, and stored at -80°C.

Cytopathic effects. Vero cells were plated in 6-well plates with 2.5 mL o f ceil
suspension added to each well and incubated at 37°C with an atmosphere o f 5% CO 2 until
confluent, about 24-48 hours. 200 pL o f appropriate concentrations o f cell-treated and
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virus-treated media were added to wells o f 6-well plate. The plate was incubated at 37°C
and an atmosphere of 5% CO 2 for an hour with intermittent rocking. Unabsorbed media
was aspirated and 3.0 ml of 5% FBS-DMEM was added to each well. The plates were
returned to the 37°C incubator with an atmosphere o f 5% CO 2 for 48 hours. Cell viability
was observed with phase contrast microscopy. The lysates o f viable cells were harvested,
transferred to cryogenic vials, and stored at -80°C.

Plaque assay.

Vero cells were plated in 6-well plates with 2.5 mL o f cell

suspension added to each well and incubated at 37°C with an atmosphere o f 5% CO 2 until
confluent, about 24-48 hours. Viral titers were determined by performing ten-fold serial
dilutions o f cell-treated and virus-treated media. To start, 1% FBS-PBS was prepared by
mixing 0.5 mL o f FBS with 49.5 mL o f PBS. 900 pL of the FBS-PBS was added to an
Eppendorf tube with 100 pL of the appropriate treated media harvested from the CPE
assay. 100 pL of this initial 10'1 dilution was then added to 900 pL o f 1% FBS-PBS to
yield the 1 0 2 dilution. Dilutions proceeded in this fashion until the 10'7 dilution was
prepared. The media was aspirated from each well of the 6-well plate and 0.5 mL o f each
corresponding dilution was added to each well on the 6-well plate starting with the 10
dilution and concluding with the 10'7 dilution. One well served as the control to which
0.5 mL of 1% FBS-PBS was added.

This dilution scheme was repeated for each

concentration o f treated media for which quantitative results were desired. The plates
were returned to a 37°C incubator with an atmosphere o f 5% CO 2 for 1 hour with
intermittent rocking. After 1 hour any unabsorbed treated media was aspirated from each
well and approximately 3 mL o f nutrient agar was poured over each well. The nutrient
agar was comprised of two components, solutions A and B. Solution A included 17 mL
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o f 3X eagle medium (Gibco Invitrogen Corporation, Grand Island, NY, USA), 1.5 mL o f
5% sodium bicarbonate (Gibco Invitrogen Corporation, Carlsbad, CA, USA), 0.5 mL
FBS, 0.1 mL DEAE-dextran (ICN Biomedicals Incorporated, Aurora, OH, USA), 0.1 mL
penicillin/streptomycin (Cambrex, Walkersville, MD, USA), and 0.05% mL gentamicin
for a total volume o f 19.25 mL. Solution B consisted o f an autoclaved solution o f 0.2 g
o f bacteriological agar (Oxoid Limited, Baskingstoke, Hampshire, England) diluted with
30 mL MQ water. Solutions A and B were tempered in a 41°C water bath. After the 1
hour incubation was complete, solutions A and B were combined and added to the wells.
The plates were stored in a 37°C incubator with an atmosphere o f 5% CO 2 for 72 hours.
The agar was then removed and the cells were stained with crystal violet. The number o f
plaques formed was counted in each well to calculate the viral titer in plaque forming
units (PFU) per milliliter.

Virus penetration assay. Vero cells were plated in 6-well plates with 2.5 mL o f
cell suspension added to each well and incubated at 37°C with an atmosphere o f 5% CO 2
until confluent, about 24-48 hours. The media was aspirated and virus suspensions were
added to each well. The plates were placed in Tupperware containers to eliminate risk o f
contamination and incubated at 4°C for 2 hours to permit viral attachment.

Serial

dilutions of 10' to 10* prepared from each treated media harvested from CPE were then
added to the appropriate wells at room temperature. The plates were incubated for 10
minutes at 37°C and atmosphere o f 5% CO 2 to allow penetration. Dilutions o f extracts
were then aspirated and the cell monolayers were briefly washed with 1% PBS. Nutrient
agar comprised o f Solution A and B was prepared as indicated previously. 2.5 mL o f the
nutrient agar was added to each well and the plates were incubated at 37°C with an
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atmosphere o f 5% CO 2 for 72 hours. The agar was removed and cell monolayers were
stained with crystal violet.

Infectious Dose 50 (ID50). Vero cells were plated in 6-well plates with 2.5 ml o f
cell suspension added to each well and incubated at 37°C and an atmosphere o f 5% CO 2
until confluent, about 24-48 hours. The media was aspirated and serial dilutions o f 10* to
10*6 were prepared from the 4% and 2% curcumin and HSV CPE lysates. The plates
were incubated at 37°C and an atmosphere o f 5% CO 2 for 1 hour with intermittent
rocking. Dilutions of unabsorbed extracts were then aspirated and 3.0 ml o f 5% FBSDMEM was added to each well. The plates were returned to the 37°C incubator with an
atmosphere o f 5% CO 2 for 48 hours. Cell viability was observed with phase contrast
microscopy. The cells were stained with crystal violet to aid in the identification o f live
cells.

DNA extraction. Vero cells plated in 60mm2 culture dishes were infected with
100 pL HSV-1 and 5% FBS-DMEM and 100 pL HSV-1, 100 pL o f the virion-treated
4% curcumin lysate, and 5% FBS-DMEM respectively.

The cells were incubated at

37°C with an atmosphere of 5% CO 2 for 18-24 hours. The DNA for each o f the two sets
o f cells was extracted with the Qiagen DNeasy® Blood & Tissue Kit (Qiagen Sciences,
Germantown, MD, USA), following the purification of total DNA from animal blood or
cells spin column protocol provided by the manufacturer.

DNA quantification. DNA was quantified in the extracted DNA products with
the NanoDrop ND-100 Spectrophotometer with the accompanying computer software
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(NanoDrop Technologies Incorporated, Wilmington, DE, USA). The standard protocol
as supplied by the manufacturer was followed.

Polymerase chain reaction (PCR).

HSV-1 DNA was amplified by PCR as

instructed by the GoTaq® PCR Core Systems quick protocol (Promega Corporation,
Madison, WI, USA).

The primers were sequence-specific for the HSV-1 strain

incorporated in all assays.

The primers coded for glycoprotein D (gD) and green

fluorescent protein (GFP). Primers included:

Glycoprotein D:

gD2F: 5’-TTGTTTGTCGTCATAGTGGGCCTC-3’

gD2R: 5 ’-TGGATCGACGGTATGTGCCAGTTT-3 ’

Green Fluorescent Protein:

GFP IF: S’-GTCAAAGCTTAAGATGGTGAGCAAGG^’
GFP 1R: 5 ’-CTTGAAGCTTCTTGTACAGCTCGTCC-3 ’

Gel electrophoresis. PCR products were visualized on a 1% agarose gel.
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Results

Cytotoxicity

Trypan blue assay. Live and dead cells for each concentration o f curcumin in
addition to positive and negative controls were counted. Live cells exclude the trypan
blue dye and therefore appear clear upon microscopic examination while dead cells
uptake the dye and appear blue upon microscopic examination. For each curcumin
concentration, the percentage of living cells was calculated by dividing the number o f
viable cells and diving by the total number o f cells (Table 1). The methanol and DMSO
served as negative controls whereas the 5% FBS-DMEM served as the positive media
control. The Vero cells successfully tolerated all concentrations o f curcumin as
compared to the positive media control (Figure 1).
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Table 1

Curcumin Cytotoxicity in Cultured Vero Cells: Trypan Blue Assay

Cur cumin

Viable

C concentration

C efls

4.00%

71% ±3%

2.00%

53% ±3%

1.00%

50% ±3%

0.50%

80% ±1%

0.25%

60% ±5%

0.125%

74% ±2%

0.06%

77% ±7%

0.03%

75% ±3%

0.015%

6"% ±3%

0 (Media)

71% ±4%

0 (DM SO)

0

0 (Methanol)

0

Note. For each sample, the percentage o f viable Vero cells was determined
microscopically by counting the number of viable (clear) and non-viable (dark blue) Vero
cells in each of the four quadrants plus the middle square on the hemacytometer. The
number of viable cells was then divided by the total number o f Vero cells for each sample
to calculate the percentages o f viable Vero cells. Values represent an average o f two
samples ±SD.
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Figure 1. Percent o f viable Vero cells after treatment with curcumin concentrations.

Viral Inhibition
Phase contrast microscopy.

To observe the cytopathic effects o f HSV-1 on

Vero cells and to determine whether curcumin could inhibit HSV-1, thereby reducing or
preventing observable cytopathic effects, cell-treated and virion-treated Vero cells were
observed with the Motic AE31 phase contrast microscope at 400X magnification at 18-24
hours post-infection. The 4% and 2% concentrations o f curcumin successfully inhibited
cytopathetic effects of HSV-1, paralleling the 5% FBS-DMEM control group. The Vero
cells infected with HSV-1 displayed rounding and detaching o f cells, characteristic
observations of cytopathetic effect.
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Plaque assay. After determining that 4% and 2% curcumin could successfully
inhibit cytopathic effects o f HSV-1 infected Vero cells, plaque assays were performed to
determine viral titer. However, the plaque assays were inconclusive as the Vero cells
lifted repeatedly from the 6-well plates when the nutrient agar was removed, resulting in
insufficient staining of the cells with crystal violet. However, no cytopathic effects were
observed when the Vero cells were viewed under phase contrast microscopy before
removal o f the agar.
Virus penetration assay. The virus penetration assay was inconclusive because
the Vero cells lifted repeatedly from the 6-well plates when the nutrient agar was
removed, resulting in insufficient staining o f the Vero cells with crystal violet. Cells
were viable and no cytopathic effects were observed with both the 4% and 2% curcumin
under phase contrast microcopy while the agar was still intact.
IDs«. The dose at which 50% or more o f the cells exhibited cytopathic effects
was determined to be 105 pfu/ml for the HSV-1 positive control, 102 pfu/ml for the 4%
curcumin and 102 pfu/ml for the 2% curcumin. This data suggests that the production o f
new HSV-1 virions was impaired
DNA extraction and com parison:

To compare the total DNA o f Vero cells

infected with HSV-1 versus the total DNA of Vero cells treated with 4% curcumin and
infected with H SV -l, DNA was extracted from the requisite Vero cells and measured
with the NanoDrop spectrophotometer. The total DNA extracted from the untreated Vero
cells measured 70.2 ng/pl and expressed a DNA/RNA A260/Protein A280 sample purity
ratio o f 1.98.

The total DNA extracted from the 4% curcumin-treated Vero cells

measured 51.7 ng/pl and expressed a DNA/RNA A260/Protein A280 sample purity ratio
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o f 2.04. This data suggests adequate purity o f the samples and a decrease in the total
amount o f DNA present in the Vero cells when the HSV-1 is exposed to the 4%
curcumin.
PCR and gel electrophoresis. To isolate the viral DNA from the total (cellular
and viral) DNA extracted from the HSV-1 infected Vero cells and the HSV-1 infected
curcumin-treated Vero cells, HSV-1 specific primers gD2 and GFP were incorporated
during PCR to amplify the viral DNA.

Gel electrophoresis o f the PCR products

displayed high intensities of bands for the HSV-1 infected cells. The bands for HSV-1
infected 4% curcumin-treated cells were lighter in intensity, suggesting that the
concentration o f viral DNA was reduced and that curcumin exerted an inhibitory effect
on HSV-1 replication (Figure 2).

26

Figure 2. Gel electrophoresis of PCR products extracted from HSV-1 infected curcumintreated and untreated cells with specific HSV-1 primers GFP and gD. Lanes 1 and 6
contain the Hi/Lo marker, lane 2 Curcumin-treated HSV-1 GFP, lane 3 HSV-1 gD, lane 4
HSV-1 GFP, lane 5 curcumin-treated HSV-1 gD..
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Discussion
As herpesvirus infections remain ubiquitous world-wide, the need for safe, effective and
inexpensive therapies to control the spread of the virus requires investigation and
development. Although the majority o f HSV infections are non-life threatening, the virus
can be fatal in the neonate and immunocompromised populations. Current HSV research
has focused on limiting the spread o f HSV within the HIV-positive population although
topical biocides and systemic antiviral therapies that eliminate the genital spread o f the
disease remain elusive to researchers and clinicians alike. Plant-derived products remain
popular choices as microbicides, especially considering their low cost, suggested
effectiveness in laboratory studies, and low toxicity (Bourne, Bourne, Reising, &
Stanberry, 1999; Harden et al., 2009). Curcumin has proven promising as a bactericidal
agent against different species o f bacteria and fungi (Beevers & Huang, 2011).
Furthermore, curcumin has demonstrated antiviral activity in HeLa cells and Vero cells
(Bourne, Bourne, Reising, & Stanberry, 1999; Kutluay, Doroghazi, Roemer, &
Triezenberg, 2008). However, the mechanism of curcumin’s inhibition o f HSV activity
has not been definitively established. Plant extracts have previously been determined to
interfere with HSV adsorption while curcumin has been implicated in the inhibition o f
viral infectivity, immediate-early gene expression and replication in Vero cell cultures
(Harden et al., 2009; Kutluay, Doroghazi, Roemer, & Triezenberg, 2008; Lin et al, 2011).
Therefore, this study aimed to determine the mechanism of curcumin’s antiviral activity
on HSV-1 in Vero cell cultures.
Viral inhibition depends upon the interruption o f one or more stages o f the virus’s
life cycle to limit and/or eliminate viral progeny. However, throughout the process of
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destroying the virus, the host cells must remain viable.

Therefore, the first step in

determining the antiviral effectiveness o f a potential therapeutic agent is to evaluate the
cytotoxicity of the agent on the host cells. The curcumin was determined to be safe at the
4% concentration and all subsequent lower concentrations. Viral inhibition o f HSV-1
was observed by the lack o f the characteristic cytopathic effects when the Vero cells were
treated with the 4% and 2% curcumin. The untreated Vero cells displayed rounding and
detaching o f cells when infected with HSV-1. Unfortunately, the determination o f viral
titer by plaque assay was inconclusive. Upon microscopic examination, the Vero cells
were viable, but enumeration was prohibited by the lifting o f the Vero cells when the
nutrient agar was discarded.

The cell monolayer was detached which made proper

staining with crystal violet unsuccessful. The explanation for this disruption o f the Vero
cell monolayer remains elusive, but the curcumin and/or DMSO may have had an effect
on the proper attachment o f the Vero cells to the plates. Both substances are nonpolar
and thus either alone or in combination may interfere with the monolayer’s remaining
fixed to the

6 -well

plates as the nutrient agar is scored and lifted from the individual

wells. The detachment o f the Vero cells also occurred during the virus penetration assay,
leading to inconclusive results as well.

However, the ID 50 assay was successful in

quantifying the infectious dose of HSV-1 in the Vero cells to be 10 pfu/ml versus the 10
pfu/ml for the 4% and 2% curcumin-treated Vero cells, respectively.

This 1000-fold

decrease in HSV-1 infectivity suggests curcumin exhibits antiviral activity against
herpesvirus. Additionally, DNA extraction of the HSV-1 infected Vero cells versus the
curcumin-treated Vero cells demonstrated a 26% reduction in total DNA from 70.2 ng/pl
to 51.7 ng/pl. This result also suggests that HSV-1 was successful at infecting Vero cells
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and that the difference in DNA concentration is due to the inhibition o f HSV-1 by
curcurmin. Amplification of PCR products with the HSV-1 specific primers gD and GFP
resulted in decreased band intensities for the 4% curcumin-treated HSV-1 for gel
electrophoresis as compared to the untreated HSV-1. This result, combined with the
decrease in total DNA in the curcumin-treated cells versus the untreated cells strongly
suggests that curcumin is inhibiting HSV replication in Vero cells.
The evidence from the assays conducted in this study collectively proposes that
curcumin exhibits an anti-viral effect on HSV-1 in Vero cell cultures. The virus appears
to adsorp and gain entrance to the cell, as demonstrated by the presence o f HSV-1 in the
PCR products. However, the replication o f HSV-1 is inhibited by the 4% curcumin as
displayed by the decrease in band intensities o f the PCR products displayed by
electrophoresis in the curcumin-treated cells versus the untreated cells. The specifics o f
the inhibition mechanism are unknown at this present time. Curcumin has been indicated
as a modulator of numerous signaling pathways, including MAPKs, PI3K/PKB, nuclear
factor kappa B (NF-kB),UPS, and COP9 signalosome (CSN) through inhibition o f casein
kinase II (CKII) and protein kinase D (PKD) (Bharti, Takada, & Aggarwai, 2004;
Chaudry & Hruska, 2003; Jana, Dikshit, Goswami, & Nukina, 2004; Kim et al., 2004;
Mullally & Fitzpatrick, 2002; Ehle et al., 2003).

Furthermore, curcumin has been

demonstrated to inhibit HSV-1 in Vero cells independent o f the p300/CBP histone
acetyltransferase pathway (Kutluay, Doroghazi, Roemer, & Triezenberg, 2008). Future
studies should focus on the effects o f curcumin on cellular signaling pathways that
contribute to successful HSV-1 replication. Additionally, the lowest dose o f curcumin
that inhibits viral replication should be established in Vero cells.

The solubility o f
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curcumin in DMSO and other organic solvents or in combination with organic solvents
and additional emulsifiers is another factor that should be investigated, as the nonpolar
nature of the curcumin and the DMSO may have had an effect on enumerating the viral
titer o f HSV-1.

The curcumin is a difficult substance to handle successfully in the

laboratory given its hydrophobic nature.
As indicated in prior research and in this study, curcumin appears to be a
promising microbicide against HSV. However, extensive research is still required to
validate the efficacy o f curcumin as an antiviral agent, both as a systemic therapeutic and
topical microbicide.
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